^
Association details:
| Biomarker: | PD-L1 expression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | IMU-201 (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer
Excerpt:
...PD-L1 expression criteria (testing by 22C3, SP142, or SP263) for...
Trial ID:
Source:
Title:
P1.15-08 - Phase 1: IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy as Monotherapy or in Combination with Atezolizumab, in Adults with Non-Small Cell Lung Cancer
Published date:
07/12/2022
Excerpt:
The IMPRINTER study is an ongoing open-label dose escalation study of IMU-201 as monotherapy (Phase 1)...for patients with PD-L1 expressing non-small cell lung cancer (NSCLC)….In Phase 1, four patients were enrolled into each of the three cohorts at 10 μg/dose, 50 μg/dose and 100 μg/dose IMU-201 with no DLTs observed. In the 10 μg/dose cohort, one patient achieved CR and one patient SD; in the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved PR and two patients achieved SD....IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy.
Source:
Title:
IMPRINTER: An open label, multicenter, dose escalation/expansion, phase 1 study of imu-201 (PD1-Vaxx), a B-cell immunotherapy as monotherapy or in combination with atezolizumab, in adults with non-small cell lung cancer (IMU.201.101).
Published date:
05/26/2022
Excerpt:
The IMPRINTER study is an ongoing open-label dose escalation study of IMU-201 as monotherapy (Phase 1) or in combination with atezolizumab (Phase 1b) for patients with PD-L1 expressing non-small cell lung cancer (NSCLC)….In Phase 1, four patients were enrolled into each of the three cohorts....In the 10 μg/dose cohort, one patient achieved CR and one patient SD; in the 50 μg/dose cohort, four patients achieved SD; and in the 100 μg/dose cohort, one patient achieved PR and two patients achieved SD....IMU-201 had no observed DLT and demonstrated preliminary signs of efficacy.
DOI:
10.1200/JCO.2022.40.16_suppl.e21134
Trial ID:
